

PuriCore plc
(“PuriCore” or the “Group” or the “Company”)

Q3 2011 Interim Management Statement
New Supermarket Retail Orders to Increase Revenues in Q4 and 2012

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 18 November 2011 — PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issues its Interim Management Statement for the third quarter and period from 1 July to 18 November 2011.

Highlights (unaudited)

- YTD (Q1 to Q3 2011) Group sales of \$28.3 million, a decrease of 6% on the comparative period last year (9% at constant currency) (YTD 2010: \$30.2 million)
- YTD Supermarket Retail sales of \$12.2 million, an increase of 2% (YTD 2010: \$12.0 million)
 - New Supermarket Retail orders representing 797 Sterilox Systems, full-year shipments expected to be approximately 1,100 Systems (FY2010: 593 Systems)
 - Two leading US supermarket chains implementing Sterilox enterprise-wide: Winn-Dixie Stores of Jacksonville, Florida, and Stater Bros Markets of San Bernardino, California
 - Second largest US supermarket retailer initiating full regional implementation, Sterilox seen as “best practice”
 - As at 30 September 2011, the Company has a total of 4,757 total Systems in place, including 644 Systems installed YTD; 42% of the target market is now either a PuriCore customer or is in a pilot programme with the Company
- YTD Endoscopy and Laboratory sales of \$15.6 million, a decrease of 13% on the comparative period last year (17% at constant currency) (YTD 2010: \$17.9 million)
 - Endoscopy recurring revenues increased 72% to \$12.6 million in the first three quarters of 2011 (YTD 2010: \$7.3 million) accounting for 80% of division sales
- YTD Wound Care (including Dental) sales of \$0.4 million, an increase of 51% (YTD 2010: \$0.3 million)
- Settlement of claim against Misonix, Inc., in connection with the acquisition of Labcaire in 2009, inclusive of a distribution agreement for a private label version of PuriCore's Wound Care solution
- \$5.9 million in cash as at 30 September 2011 (30 September 2010: \$8.5 million)
- The Board continues its discussions with bondholders on its options relating to the £7.95 million convertible loan notes repayable on 31 December 2011 and will make an announcement in due course

Post Balance-Sheet Events

- New line of Vashe Wound Therapy for Instillation Applications launched in November, suitable for adjunctive therapies (e.g. ultrasonic debridement and negative-pressure wound therapy)

Business Report

PuriCore sales of \$28.3 million for the first three quarters of 2011 decreased slightly compared with the previous year (\$30.2 million) primarily due to delays in capital spending by the UK National Health Service (NHS). Sales for the three quarters in the UK Endoscopy and Laboratory business decreased 13% (17% at constant currency). Whilst sales to supermarket retail chains increased slightly (2%) compared with the same period last year, sales activity is robust with significant new orders expected to increase revenues in Q4 2011 and Q1 2012. In the Wound Care business, sales from Vashe Wound Therapy (including Dental sales) achieved a 51% increase for the three quarters over the same period in 2010.

In July, the Company announced that a settlement had been reached with Misonix following its January 2011 Particulars of Claim against Misonix, Inc., the seller of the Labcaire business, in which PuriCore sought damages in excess of £2.1 million for breaches of warranty under the Sale and Purchase Agreement (SPA) in connection with PuriCore's acquisition of Labcaire in August 2009. As part of the settlement, PuriCore is no longer liable for \$1 million in commission payments as defined in the SPA, and Misonix reimbursed PuriCore \$650,000 towards costs and fees of the litigation to date. The companies simultaneously agreed to enter into a distribution agreement for a private label version of PuriCore's Wound Care solution for use principally in conjunction with the Misonix line of ultrasonic systems. As part of this agreement, Misonix has the obligation over a three-year period either to purchase product or pay minimum payments of \$2 million in gross margin value to PuriCore, which will thereby underpin the profitability of this growing division.

The Supermarket Retail business nearly doubled its installations in the third quarter, bringing the total YTD to 644 Systems. PuriCore now has installed 17% of the target market in the US and Canada with a total of 4,757 Systems now in place. In total, 42% of the target market is now either a PuriCore customer or is in a pilot programme with the Company. New orders received in Q3 include 797 Systems, including major new enterprise-wide contracts from two new leading US supermarket customers, Winn-Dixie Stores and Stater Bros Markets, in addition to full adoption now underway in one regional division of the second largest US supermarket retailer. As communicated in PuriCore's Q1 IMS, this year the Company expected to install a multiple of the 593 Systems delivered in 2010. The Company now estimates that approximately 1,100 Systems will be shipped for the full year, with continued volume growth into 2012 as the Company will begin the year with significant orders already in hand.

As previously reported, the primary UK customer, the NHS, initiated capital spending constraints as it started its fiscal year in April. Whilst these purchasing delays continue to contribute to lower than expected sales YTD, the NHS supply chain and purchasing process is expected to improve in Q4 2011. In addition, recurring revenues continued to increase YTD, up 72% to \$12.6 million in the first three quarters of 2011 (YTD 2010: \$7.3 million), accounting for 80% of division sales for the first nine months of 2011. This higher proportion was the result of the UK NHS capital spending constraints as well as the Company's continued focus to increase growth of rentals and recurring revenues.

In the Wound Care business (including Dental), sales increased 51% in first nine months of 2011 to \$0.4 million compared with the same period in 2010, nearly all attributable to the new bottled Vashe Wound Therapy. This new bottled product currently offers a 12-month shelf-life for use in both wound care clinics and patient use at home. Future sales will be boosted both by organic growth of the Vashe business as well as by the distribution agreement with Misonix, initiating in Q4 2011 and continuing through 2014. In addition, the Company recently

launched a new line of Vashe Wound Therapy for Instillation Applications. This product offers a controlled flow of Vashe solution, addressing increasing prevalence of adjunctive therapies such as ultrasonic debridement and negative-pressure wound therapy.

Convertible Loan Notes

The Company announced on 21 October 2011 the position regarding its £7.95 million of convertible loan notes issued by the Company on 14 June 2010, details of which were announced and set out in a circular to shareholders on 28 May 2010. The Convertible Loan Notes, amounting to £7.95 million, are repayable on 31 December 2011 subject to the holders having the right to convert all or part of their holdings into ordinary shares of the Company at a price (following the consolidation of the share capital on 14 June 2010) of 75p per share.

The Board continues to hold discussions with the bondholders in relation to the loan notes and will make an announcement in due course. It is emphasised that whilst the Board is actively considering all its options as outlined in its October announcement, there is no certainty that all or any of these options will be achievable.

Chris Wightman, Executive Chairman of PuriCore, said:

“Whilst year-to-date sales for PuriCore were slightly down, we are confident of a strong finish to the year with some easing of spending restraints by the UK NHS, robust installations of our Sterilox Systems in the Food Retail sector, and continued growth in our Wound Care business.

“In the Supermarket Retail business, major orders in Q3 from two new leading retailer customers combined with the increased pace of installations at the second largest retailer in the US will drive strong revenues in Q4 and continue into 2012. With these new orders, we expect total installations in 2011 will be approximately 1,100, significantly higher than the 593 installations in 2010. The considerable increase in installations for our Systems suggests our technology is becoming the de facto standard for supermarket retailers across the US.

“With the ongoing capital purchasing delays in the UK, we have continued to focus on increasing recurring revenue, with a 72% increase in 2011, in order to insulate the business from NHS spending policy changes though we are seeing some easing of NHS spending constraints in Q4 and into 2012.

“Our Wound Care business shows steady growth as the awareness and acceptance of our bottled Vashe product expands with healthcare providers and key opinion leaders. Our new Vashe product line for Instillation Applications opens a new rapidly expanding class of use in adjunct wound care treatments. Later this year, revenues are expected from our new distribution agreement with Misonix, further expanding our reach in the wound care market and underpinning profitability for this division in the future.

“The Board remains confident in the future profitability of each division individually and for the business collectively in 2012. We believe the current business mix will deliver both robust growth and significant cash generation and that we will continue to make progress on promising new business opportunities.”

Enquiries:

FTI Consulting
Susan Quigley
Ben Brewerton

PuriCore
Chris Wightman
Executive Chairman

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of *C.difficile*, *E.coli*, HIV, Human and Animal Influenza (including H1N1 and H5N1), *Legionella*, *MRSA*, *M.tuberculosis*, Norovirus, and *Salmonella*. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.